GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Rhinomed Ltd (ASX:RNO) » Definitions » Gross Margin %

Rhinomed (ASX:RNO) Gross Margin % : 80.39% (As of Jun. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Rhinomed Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Rhinomed's Gross Profit for the six months ended in Jun. 2023 was A$3.29 Mil. Rhinomed's Revenue for the six months ended in Jun. 2023 was A$4.09 Mil. Therefore, Rhinomed's Gross Margin % for the quarter that ended in Jun. 2023 was 80.39%.


The historical rank and industry rank for Rhinomed's Gross Margin % or its related term are showing as below:

ASX:RNO' s Gross Margin % Range Over the Past 10 Years
Min: 49.77   Med: 69.93   Max: 77.4
Current: 74.82


During the past 13 years, the highest Gross Margin % of Rhinomed was 77.40%. The lowest was 49.77%. And the median was 69.93%.

ASX:RNO's Gross Margin % is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 53.575 vs ASX:RNO: 74.82

Rhinomed had a gross margin of 80.39% for the quarter that ended in Jun. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Rhinomed was 1.20% per year.


Rhinomed Gross Margin % Historical Data

The historical data trend for Rhinomed's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rhinomed Gross Margin % Chart

Rhinomed Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 66.74 59.33 70.68 68.16 74.83

Rhinomed Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 75.32 64.36 70.82 68.09 80.39

Competitive Comparison of Rhinomed's Gross Margin %

For the Medical Devices subindustry, Rhinomed's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rhinomed's Gross Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Rhinomed's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Rhinomed's Gross Margin % falls into.



Rhinomed Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Rhinomed's Gross Margin for the fiscal year that ended in Jun. 2023 is calculated as

Gross Margin % (A: Jun. 2023 )=Gross Profit (A: Jun. 2023 ) / Revenue (A: Jun. 2023 )
=5.6 / 7.472
=(Revenue - Cost of Goods Sold) / Revenue
=(7.472 - 1.881) / 7.472
=74.83 %

Rhinomed's Gross Margin for the quarter that ended in Jun. 2023 is calculated as


Gross Margin % (Q: Jun. 2023 )=Gross Profit (Q: Jun. 2023 ) / Revenue (Q: Jun. 2023 )
=3.3 / 4.089
=(Revenue - Cost of Goods Sold) / Revenue
=(4.089 - 0.802) / 4.089
=80.39 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Rhinomed  (ASX:RNO) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Rhinomed had a gross margin of 80.39% for the quarter that ended in Jun. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Rhinomed Gross Margin % Related Terms

Thank you for viewing the detailed overview of Rhinomed's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Rhinomed (ASX:RNO) Business Description

Traded in Other Exchanges
Address
132 Gwynne Street, Level 1, Cremorne, VIC, AUS, 3121
Rhinomed Ltd is a medical technology company, with a patented nasal technology platform. It is engaged in the research, development and commercialization of consumer and medical devices including nasal, respiratory and nasal drug delivery technologies. It operates in one segment which is the identification, acquisition, and commercialization of late-stage consumer therapeutic and medical delivery technologies. The products of the company involve Rhinoswab, Mute, Turbine and Rhinoswab Junior. It operates geographically within North, Central, and South America, Asia-Pacific, Europe, Middle East, and Africa. The company earns majority of its revenue from Asia-Pacific.

Rhinomed (ASX:RNO) Headlines

No Headlines